<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852020000500005</article-id>
<article-id pub-id-type="doi">10.48193/revistamexicanadeurologa.v80i5.699</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Utilidad del 18-FDG-PET/CT para determinar viabilidad tumoral en manejo de masas residuales de seminoma posquimioterapia]]></article-title>
<article-title xml:lang="en"><![CDATA[Utility of 18F-FDG PET/CT in determining tumor viability in post-chemotherapy management of residual seminomatous masses]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mamani-Flores]]></surname>
<given-names><![CDATA[Efraín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Toriz]]></surname>
<given-names><![CDATA[Narciso]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Huerta-Gómez]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quintero-Becerra]]></surname>
<given-names><![CDATA[Joel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ayala-Quispe]]></surname>
<given-names><![CDATA[Vianey Brígida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Siglo XXI ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Centro Médico Nacional &#8220;20 de noviembre&#8221; ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2020</year>
</pub-date>
<volume>80</volume>
<numero>5</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852020000500005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852020000500005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852020000500005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: En las últimas décadas, el manejo posquimioterapia de seminoma ha evolucionado debido al uso creciente de tomografía por emisión de positrones con 18 fluoro-desoxi-D-glucosa (18-FDG-PET) este método solo o combinado con la tomografía computarizada (CT) se ha propuesto como herramienta no invasiva para evaluar la extensión de la enfermedad. El objetivo fue conocer su utilidad para determinar viabilidad tumoral en el manejo de masas residuales retroperitoneales de seminoma posquimioterapia.  Material y Métodos: Estudio retrospectivo monocéntrico, se revisaron expedientes clínicos de 53 pacientes durante 2013-2018. Se definió respuesta a tratamiento mediante criterios de Recist 1.1 por CT y viabilidad tumoral mediante SUV Max por 18-FDG-PET/CT. Según resultado se dividió en grupos: vigilancia, cirugía de rescate, radioterapia y quimioterapia. En el grupo de cirugía (n=17) se correlaciono PET/CT y estudio histopatológico (estándar de oro). El análisis estadístico incluyo el cálculo de sensibilidad (S), especificidad (E) y valores predictivos positivo (VPP) y negativo (VPN) mediante el análisis del área bajo la curva de características receptor-operador (ROC), se utilizó el software SPSS v24.  Resultados: Al analizar, sin discriminar por grupos, se encontró una curva ROC con punto de corte de 3.150, S 50% y E 60%, valores que no son discriminativos ni útiles para definir viabilidad tumoral. Al analizar el grupo de cirugía de rescate se obtuvieron S 100%, E 25%, VPP 35% y VPN 100%.  Conclusiones: Primer estudio realizado en el país, el 18 FDG-PET/CT demostró una utilidad muy pobre para discriminar viabilidad tumoral en masas residuales seminomatosas posquimioterapia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: In recent decades, post-chemotherapy management of seminoma has advanced due to the increased use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). Said method alone or combined with computed tomography (CT) has been proposed as a noninvasive tool for evaluating disease extension. Our aim was to determine its utility in describing tumor viability in the post-chemotherapy management of retroperitoneal residual seminomatous masses.  Materials and methods: A retrospective single-center study was conducted. The clinical case records of 53 patients seen within the time frame of 2013-2018 were reviewed. Treatment response was defined by the Recist 1.1 criteria (for CT) and tumor viability through the SUVmax (in 18F-FDG-PET). According to the results, the patients were divided into groups: surveillance, rescue surgery, radiotherapy, and chemotherapy. The PET/CT result was correlated with the histopathologic study (gold standard) in the surgery group (n=17). In the statistical analysis, sensitivity (S), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) were calculated through the area under the receiver operating characteristics (AUROC) curve. The SPSS v24 software was utilized.  Results: The analysis, with no group discrimination, produced an ROC curve with a cutoff point of 3.150, S 50%, and Sp 60%, values that are neither discriminatory nor useful for defining tumor viability. The rescue surgery group analysis produced S 100%, Sp 25%, PPV 35%, and NPV 100%.  Conclusions: In this first Mexican study, 18F-FDG-PET/CT demonstrated very poor utility for determining tumor viability in post-chemotherapy residual seminomatous masses.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[18F-FDG-PET/CT]]></kwd>
<kwd lng="en"><![CDATA[Seminoma]]></kwd>
<kwd lng="en"><![CDATA[Post-chemotherapy residual masses.]]></kwd>
<kwd lng="es"><![CDATA[18-FDG-PET/CT]]></kwd>
<kwd lng="es"><![CDATA[seminoma]]></kwd>
<kwd lng="es"><![CDATA[masas residuales posquimioterapia.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Treglia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sadeghi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Annunziata]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Caldarella]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bertagna]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Giovanella]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis]]></article-title>
<source><![CDATA[Biomed Res Int]]></source>
<year>2014</year>
<volume>2014</volume>
<page-range>852681</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carver]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Serio]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Bajorin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Motzer]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stasi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bosl]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2007</year>
<volume>25</volume>
<numero>35</numero>
<issue>35</issue>
<page-range>5603-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krege]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Beyer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Souchon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Albers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Albrecht]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Algaba]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2008</year>
<volume>53</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>497-513</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmoll]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Souchon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Krege]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Albers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Beyer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kollmannsberger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2004</year>
<volume>15</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1377-99</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thüer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Polyakov]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2008</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>260-72</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peckham]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Horwich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hendry]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8)]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>1985</year>
<volume>52</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-13</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quek]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Simma-Chiang]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Pinski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postchemotherapy residual masses in advanced seminoma: current management and outcomes]]></article-title>
<source><![CDATA[Expert Rev Anticancer Ther]]></source>
<year>2005</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>869-74</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herr]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Sheinfeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Puc]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Heelan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bajorin]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Mencel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgery for a post-chemotherapy residual mass in seminoma]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>1997</year>
<volume>157</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>860-2</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Altamirano-Ley]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta-Borbón]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa-Carrillo]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vásquez-Escobar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Rojas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Estrada]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valor estandarizado de captación máximo, determinado con Tomografía por Emisión de Positrones y Tomografía Computarizada. &#8220;Primera experiencia en México&#8221;]]></article-title>
<source><![CDATA[Anales de Radiología México]]></source>
<year>2007</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>113-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Treglia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cason]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fagioli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent applications of nuclear medicine in diagnostics (I part)]]></article-title>
<source><![CDATA[Italian Journal of Medicine]]></source>
<year>2010</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>84-91</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hinz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schrader]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kempkensteffen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bares]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brenner]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Krege]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2008</year>
<volume>179</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johns Putra]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrentschuk]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ballok]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hannah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Poon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tauro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy]]></article-title>
<source><![CDATA[Urology]]></source>
<year>2004</year>
<volume>64</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1202-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Becherer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bokemeyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stoiber]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Oechsle]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sellner]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2004</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1034-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cervera Deval]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[RECIST y el radiólogo]]></article-title>
<source><![CDATA[Radiologia]]></source>
<year>2014</year>
<volume>56</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>193-205</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lavery]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bahnson]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Sharp]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Pohar]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors]]></article-title>
<source><![CDATA[Ther Adv Urol]]></source>
<year>2009</year>
<volume>1</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>199-207</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ganjoo]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Einhorn]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1999</year>
<volume>17</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3457-60</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hain]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Doherty]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Timothy]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Leslie]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Harper]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Huddart]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2000</year>
<volume>83</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>863-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spermon]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[De Geus-Oei]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Kiemeney]]></surname>
<given-names><![CDATA[L a. LM]]></given-names>
</name>
<name>
<surname><![CDATA[Witjes]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Oyen]]></surname>
<given-names><![CDATA[WJG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours]]></article-title>
<source><![CDATA[BJU Int]]></source>
<year>2002</year>
<volume>89</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>549-56</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Tann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kesler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[McCool]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Einhorn]]></surname>
<given-names><![CDATA[LH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2006</year>
<volume>24</volume>
<numero>34</numero>
<issue>34</issue>
<page-range>e54-5</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siekiera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ma&#322;kowski]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jó&#378;wicki]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Jasi&#324;ski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wronczewski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pietrzak]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can We Rely on PET in the Follow-Up of Advanced Seminoma Patients?]]></article-title>
<source><![CDATA[UIN]]></source>
<year>2012</year>
<volume>88</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>405-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bachner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Loriot]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gross-Goupil]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zucali]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Horwich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Germa-Lluch]]></surname>
<given-names><![CDATA[J-R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2012</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-64</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ambrosini]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Zucchini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berselli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nanni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Allegri]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[18F-FDG PET/CT impact on testicular tumours clinical management]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2014</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>668-73</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bilen]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Hariri]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Leon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Kuban]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Pisters]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature]]></article-title>
<source><![CDATA[Clin Genitourin Cancer]]></source>
<year>2014</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e147-50</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
